Deciphera Pharmaceuticals LLC

173 articles with Deciphera Pharmaceuticals LLC

• Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations

  11/30/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), today announced a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend the Company’s cash runway.

• 

  Deciphera Cutting 35% of Staff Amid Company Restructure

  11/30/2021

  Deciphera Pharmaceuticals announced it is restructuring with the intention of prioritizing clinical development of specific programs and streamlining its commercial operations.

• Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

  11/22/2021

  Deciphera Receives European Commission Approval of QINLOCK ® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor.

• Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study

  11/5/2021

  Deciphera Pharmaceuticals, Inc. today announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib.

• Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results

  11/2/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.

• Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021

  10/26/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its third quarter 2021 financial results on Tuesday, November 2, 2021.

• Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

  10/12/2021

  Deciphera Announces Approval of QINLOCK ® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

• Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  10/7/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced the presentation of preclinical data from the Company’s first-in-class selective ULK kinase inhibitor, DCC-3116, in combination with EGFR inhibitors in non-small cell lung cancer (NSCLC) models at the AACR-NCI-EORTC International Conference.

• Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor

  9/17/2021

  Deciphera Announces Positive CHMP Opinion for QINLOCK ® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor

• Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021

  9/17/2021

  Deciphera Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced four e-poster presentations at the ESMO Congress 2021.

• Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021

  9/10/2021

  Deciphera Pharmaceuticals, Inc. today announced that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021 on Friday, September 17, 2021, from 10:00 AM to 12:30 PM ET.

• Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

  9/2/2021

  Deciphera Pharmaceuticals, Inc. announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET.

• Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals

  8/3/2021

  Sprint Bioscience AB announces that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals.

• Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results

  8/3/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended June 30, 2021 and provided a corporate update.

• Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021

  7/27/2021

  Deciphera Pharmaceuticals, Inc. announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021.

• Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene

  6/30/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced dose administration for the first patient in the Phase 1, multicenter, open-label, first-in-human study of DCC-3116.

• Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

  5/27/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in fireside chats at the following investor conferences: Jefferies Virtual Healthcare Conference on June 3, 2021 at 1:30 PM ET JMP Securities Life Sciences Conference on June 16, 2021 at 4:00 PM ET

• Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results

  5/4/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2021, and provided a corporate update.

• Deciphera Pharmaceuticals, Inc. to Present at the Truist Securities Life Sciences Summit

  4/28/2021

  Deciphera Pharmaceuticals, Inc. to Present at the Truist Securities Life Sciences Summit

• Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021

  4/27/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, May 4, 2021, to discuss the Company’s financial results and provide a corporate update.